Journal: Scientific reports
This retrospective bicentric cohort study evaluated the real-world efficacy and safety of adjuvant trastuzumab emtansine (T-DM1) in 102 HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy at Institut Curie Hospitals.
After a median follow-up of 44 months, the 4-year disease-free survival rate was 92.5%. Lymph node involvement at diagnosis was the only factor significantly associated with relapse risk.
Seven patients experienced distant recurrence, predominantly CNS metastases.
Dose reductions and treatment discontinuations occurred in 33% and 23% of patients, respectively, mainly due to peripheral neuropathy and thrombocytopenia.
Grade 3-4 toxicities occurred in 9% of patients, with no treatment-related deaths.
Overall outcomes:
- Align with the KATHERINE trial
- Highlight T-DM1’s efficacy
- Indicate the need for therapies with better CNS penetration